Abstract
Lutathera® has been reimbursed in the UK since 2018 for treatment of unresectable or metastatic, progressive, well-differentiated, somatostatin positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. This analysis aimed to explore healthcare resource use and costs in England for progressive NET patients treated with Lutathera® and matched patients treated with somatostatin analogues (SSAs), chemotherapy, or targeted therapies (everolimus or sunitinib).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
